Zhitong Finance App News, China Biopharmaceutical (01177) announced that the TQH5528 “oral STAT6 degradant” independently developed by the group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (“Zhengda Tianqing”), published pre-clinical research data in the form of an oral report (Oral) at the 2026 meeting of the European Respiratory Society (ERS 2026) and simultaneously displayed an electronic poster (e-poster).

TQH5528 is an oral STAT6 degrading agent developed by Chia Tai Tianqing based on the global oral protein degrading agent technology platform (OAPD®) with independent intellectual property rights. TQH5528 targets the IL-4/IL-13/STAT6 signal axis, relies on proteolytic mechanisms to exert efficacy, and has the potential to become a next-generation therapeutic drug that is more convenient to administer as an alternative to injecting biological agents.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.